The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings.
The participants will be treated with maribavir for up to 8 weeks.
Hematopoietic Stem Cell Transplant Recipients
Adult patients with an expected survival of ≥4 weeks.
Confirmed CMV infection, including CMV viremia and CMV disease.
Fully understand the content of the trial, voluntarily participate and complete the trial, and voluntarily sign the informed consent form.
Patients currently participating in other CMV-related clinical studies, such as those receiving anti-CMV drug treatment or involved in CMV vaccine clinical studies.
At screening, liver function tests show: AST > 5×ULN, or ALT > 5×ULN, or total bilirubin ≥ 3.0×ULN.
Patients with psychiatric disorders or severe psychological conditions that may affect the ability to provide informed consent or participate in follow-up consultations.
Participants deemed unsuitable for inclusion by the investigator.